Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Semin Nephrol. 2011 May;31(3):310-6. doi: 10.1016/j.semnephrol.2011.05.010.
Nephrogenic systemic fibrosis is a new disease whose incidence has peaked and receded over the past decade. It occurs in the presence of significant renal impairment, either acute or chronic (MDRD creatinine clearance of <30 mL/min/1.73 m(2)), and is associated with the administration of gadolinium-based contrast (GBC). Since 2006, the incidence of this disease has decreased markedly in patients with renal impairment, mainly owing to protocols that have not administered GBC to patients with creatinine clearances of less than 30 mL/min/1.73 m(2), and in some cases with the use of less toxic and lower doses of GBC. The purpose of this article is to review the current status of GBC use for imaging in patients with kidney disease.
肾源性系统性纤维化是一种新出现的疾病，其发病率在过去十年中已达到峰值并有所下降。它发生在存在明显的肾功能损害的情况下，无论是急性还是慢性的（MDRD 肌酐清除率<30 mL/min/1.73 m(2)），并且与钆基造影剂（GBC）的给药有关。自 2006 年以来，肾功能损害患者中这种疾病的发病率显著下降，这主要归因于那些未向肌酐清除率<30 mL/min/1.73 m(2)的患者给予 GBC 的方案，在某些情况下还使用了毒性更低、剂量更低的 GBC。本文旨在回顾用于肾病患者成像的 GBC 使用的现状。
